Graft-specific inhibition of complement activation after xenotransplantation; genetically modified pig organs versus systemic anticomplement strategies
Dorling, A.
Transplantation 69(6): 1033-1034
2000
ISSN/ISBN: 0041-1337 PMID: 10762202 Document Number: 512723
Document emailed within 1 workday
Related Documents
Maurer-Gebhard, M.; Schmidt, M.; Azemar, M.; Altenschmidt, U.; Stöcklin, E.; Wels, W.; Groner, B. 1998: Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells Cancer Research 58(12): 2661-2666Tanaka, M.; Murase, N.; Miyazawa, H.; Ye, Q.; Manez, R.; Todo, S.; Demetris, A.J.; Nomoto, M.; Miyazaki, W.; Starzl, T.E. 1995: Effect of anticomplement agent K-76 COOH in hamster-to-rat and guinea pig-to-rat xenotransplantation Transplantation Proceedings 27(1): 275-276
Di Perri, T.; Auteri, A.; Pasini, F.L.; Mattioli, F. 1977: Inhibition by cinnarizine of the properdin-dependent activation of complement Archives Internationales de Pharmacodynamie et de Therapie 226(2): 281-285
Miyamoto, Y. 1986: Clinical study of complement activation during cardiopulmonary bypass--analyses of complement activation pathway and transpulmonary leukosequestration Nihon Kyobu Geka Gakkai 34(12): 2055-2061
Schirrmacher, V.; von Hoegen, P.; Heicappell, R. 1989: Virus modified tumor cell vaccines for active specific immunotherapy of micrometastases: expansion and activation of tumor-specific T cells Progress in Clinical and Biological Research 288: 391-399
Ojima, T.; Iwahashi, M.; Nakamura, M.; Matsuda, K.; Nakamori, M.; Ueda, K.; Naka, T.; Katsuda, M.; Miyazawa, M.; Iida, T.; Yamaue, H. 2008: Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA International Journal of Oncology 32(2): 459-466
Berthoux, F.C.; Freyria, A.M. 1980: Specific measurement of alternate pathway activation of complement in human glomerulonephritides (GN): 125 cases Nephrologie 1(2): 61-66
Kozlov, L.V.; Sizoĭ, M.N.; Zinchenko, A.A.; Levkovskiĭ, A.V. 1986: Inhibition of the binding and activation of the first component of human complement. The effect of synthetic peptides, immunoglobulin fragments and various proteins Biokhimiia 51(5): 707-718
Simakhodskiĭ, A.S.; Sofronov, B.N.; Purin', V.I. 1981: Determination of circulating immune complexes by complement microfixation in studies on serum anticomplement activity Laboratornoe Delo 1981(6): 351-353
Weiler, J.M.; Edens, R.E.; Linhardt, R.J.; Kapelanski, D.P. 1992: Heparin and modified heparin inhibit complement activation in vivo Journal of Immunology 148(10): 3210-3215
Bunk, A.; Dapper, F.; Hata, H.; Neuhof, H.; Hehrlein, F.W. 1993: Experimental studies of the influence of priming solutions on the systemic activation of complement during cardiopulmonary bypass: comparison between the use of albumin, hydroxyethyl starch and HWA-138 Journal of Cardiovascular Surgery 34(2): 115-122
Arvieux, J.; Roussel, B.; Ponard, D.; Colomb, M.G. 1991: Reactivity patterns of anti-phospholipid antibodies in systemic lupus erythematosus sera in relation to erythrocyte binding and complement activation Clinical and Experimental Immunology 84(3): 466-471
Jackson, W.T.; Boyd, R.J.; Froelich, L.L.; Mallett, B.E.; Gapinski, D.M. 1992: Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982 Journal of Pharmacology and Experimental Therapeutics 263(3): 1009-1014
Berthoux, F.C.; Freyria, A.M.; Traeger, J. 1977: Anticomplement activity of a polyanion: pentosan sulfuric polyester. III. Mechanism of functional inactivation of the different properdin and complement system fractions Pathologie-Biologie 25(3): 179-184
Divanian, K. 1986: Antigen-specific inhibition of donor cell activity in the graft vs. host reaction Eksperimentalna Meditsina i Morfologiia 25(4): 47-49
Cary, N.; Moody, J.; Yannoutsos, N.; Wallwork, J.; White, D. 1993: Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection Transplantation Proceedings 25(1 Pt 1): 400-401
Bouwman, E.; de Bruin, R.W.; Marquet, R.L.; Jeekel, J. 1989: Prolongation of graft survival in sensitized xenotransplantation Transplantation Proceedings 21(1 Part 1): 551-552
Klein, G.; Vonka, V. 1974: Relationship between Epstein-Barr virus-determined complement-fixing antigen and nuclear antigen detected by anticomplement fluorescence Journal of the National Cancer Institute 53(6): 1645-1646
Fidler, I.J.; Fogler, W.E.; Brownbill, A.F.; Schumann, G. 1987: Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide Journal of Immunology 138(12): 4509-4514
Bach, F.H.; Robson, S.C.; Ferran, C.; Millan, M.; Anrather, J.; Kopp, C.; Lesnikoski, B.; Goodman, D.J.; Hancock, W.W.; Wrighton, C. 1995: Xenotransplantation: endothelial cell activation and beyond Transplantation Proceedings 27(1): 77-79